nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABL1—Parkinson's disease	0.47	0.692	CbGaD
Ponatinib—CYP2D6—Parkinson's disease	0.122	0.179	CbGaD
Ponatinib—ABCB1—Parkinson's disease	0.0869	0.128	CbGaD
Ponatinib—RET—enteric nervous system—Parkinson's disease	0.0117	0.101	CbGeAlD
Ponatinib—SRC—adrenal medulla—Parkinson's disease	0.00743	0.0641	CbGeAlD
Ponatinib—KIT—myenteric nerve plexus—Parkinson's disease	0.00585	0.0505	CbGeAlD
Ponatinib—RET—autonomic nervous system—Parkinson's disease	0.00411	0.0354	CbGeAlD
Ponatinib—FGFR4—hindbrain—Parkinson's disease	0.00368	0.0317	CbGeAlD
Ponatinib—Nilotinib—MAPK8—Parkinson's disease	0.00248	0.318	CrCbGaD
Ponatinib—FGFR4—embryo—Parkinson's disease	0.0023	0.0199	CbGeAlD
Ponatinib—FGFR4—brainstem—Parkinson's disease	0.00211	0.0182	CbGeAlD
Ponatinib—Imatinib—NQO2—Parkinson's disease	0.002	0.256	CrCbGaD
Ponatinib—FGFR2—hindbrain—Parkinson's disease	0.00164	0.0142	CbGeAlD
Ponatinib—FGFR3—embryo—Parkinson's disease	0.00157	0.0135	CbGeAlD
Ponatinib—FGFR3—forebrain—Parkinson's disease	0.00139	0.012	CbGeAlD
Ponatinib—Nilotinib—ABL1—Parkinson's disease	0.00126	0.161	CrCbGaD
Ponatinib—BCR—forebrain—Parkinson's disease	0.0012	0.0104	CbGeAlD
Ponatinib—FGFR4—head—Parkinson's disease	0.00117	0.0101	CbGeAlD
Ponatinib—KIT—hindbrain—Parkinson's disease	0.00114	0.00985	CbGeAlD
Ponatinib—FGFR4—nervous system—Parkinson's disease	0.00111	0.00953	CbGeAlD
Ponatinib—RET—embryo—Parkinson's disease	0.00108	0.00933	CbGeAlD
Ponatinib—FGFR4—central nervous system—Parkinson's disease	0.00106	0.00918	CbGeAlD
Ponatinib—Imatinib—ABL1—Parkinson's disease	0.00105	0.134	CrCbGaD
Ponatinib—FGFR4—cerebellum—Parkinson's disease	0.00104	0.00897	CbGeAlD
Ponatinib—FGFR2—embryo—Parkinson's disease	0.00103	0.00887	CbGeAlD
Ponatinib—FLT3—cardiovascular system—Parkinson's disease	0.00101	0.00871	CbGeAlD
Ponatinib—FGFR3—medulla oblongata—Parkinson's disease	0.001	0.00866	CbGeAlD
Ponatinib—ABL1—hindbrain—Parkinson's disease	0.000994	0.00857	CbGeAlD
Ponatinib—TEK—embryo—Parkinson's disease	0.000986	0.0085	CbGeAlD
Ponatinib—FGFR2—brainstem—Parkinson's disease	0.000942	0.00813	CbGeAlD
Ponatinib—FGFR3—midbrain—Parkinson's disease	0.000917	0.00791	CbGeAlD
Ponatinib—FGFR2—forebrain—Parkinson's disease	0.000909	0.00784	CbGeAlD
Ponatinib—FGFR3—spinal cord—Parkinson's disease	0.000895	0.00772	CbGeAlD
Ponatinib—PDGFRA—embryo—Parkinson's disease	0.000893	0.0077	CbGeAlD
Ponatinib—SRC—embryo—Parkinson's disease	0.000876	0.00755	CbGeAlD
Ponatinib—BCR—medulla oblongata—Parkinson's disease	0.000868	0.00749	CbGeAlD
Ponatinib—FGFR4—brain—Parkinson's disease	0.000845	0.00729	CbGeAlD
Ponatinib—KDR—embryo—Parkinson's disease	0.000805	0.00695	CbGeAlD
Ponatinib—LYN—head—Parkinson's disease	0.000799	0.0069	CbGeAlD
Ponatinib—FGFR3—head—Parkinson's disease	0.000795	0.00686	CbGeAlD
Ponatinib—BCR—midbrain—Parkinson's disease	0.000794	0.00685	CbGeAlD
Ponatinib—PDGFRA—forebrain—Parkinson's disease	0.00079	0.00681	CbGeAlD
Ponatinib—SRC—forebrain—Parkinson's disease	0.000774	0.00668	CbGeAlD
Ponatinib—BCR—spinal cord—Parkinson's disease	0.000774	0.00668	CbGeAlD
Ponatinib—FGFR1—medulla oblongata—Parkinson's disease	0.000773	0.00666	CbGeAlD
Ponatinib—FGFR2—cardiovascular system—Parkinson's disease	0.000769	0.00663	CbGeAlD
Ponatinib—LYN—nervous system—Parkinson's disease	0.000758	0.00654	CbGeAlD
Ponatinib—FGFR3—nervous system—Parkinson's disease	0.000754	0.0065	CbGeAlD
Ponatinib—TEK—cardiovascular system—Parkinson's disease	0.000737	0.00636	CbGeAlD
Ponatinib—LYN—central nervous system—Parkinson's disease	0.00073	0.0063	CbGeAlD
Ponatinib—FGFR3—central nervous system—Parkinson's disease	0.000726	0.00626	CbGeAlD
Ponatinib—KIT—embryo—Parkinson's disease	0.000714	0.00616	CbGeAlD
Ponatinib—KDR—forebrain—Parkinson's disease	0.000712	0.00615	CbGeAlD
Ponatinib—FGFR3—cerebellum—Parkinson's disease	0.00071	0.00612	CbGeAlD
Ponatinib—FGFR1—midbrain—Parkinson's disease	0.000706	0.00609	CbGeAlD
Ponatinib—RET—medulla oblongata—Parkinson's disease	0.000691	0.00596	CbGeAlD
Ponatinib—FGFR1—spinal cord—Parkinson's disease	0.000689	0.00594	CbGeAlD
Ponatinib—BCR—head—Parkinson's disease	0.000688	0.00594	CbGeAlD
Ponatinib—PDGFRA—cardiovascular system—Parkinson's disease	0.000668	0.00576	CbGeAlD
Ponatinib—SRC—cardiovascular system—Parkinson's disease	0.000655	0.00565	CbGeAlD
Ponatinib—KIT—brainstem—Parkinson's disease	0.000654	0.00564	CbGeAlD
Ponatinib—BCR—nervous system—Parkinson's disease	0.000652	0.00563	CbGeAlD
Ponatinib—RET—midbrain—Parkinson's disease	0.000632	0.00545	CbGeAlD
Ponatinib—TEK—medulla oblongata—Parkinson's disease	0.00063	0.00543	CbGeAlD
Ponatinib—BCR—central nervous system—Parkinson's disease	0.000628	0.00542	CbGeAlD
Ponatinib—ABL1—embryo—Parkinson's disease	0.000621	0.00536	CbGeAlD
Ponatinib—RET—spinal cord—Parkinson's disease	0.000616	0.00532	CbGeAlD
Ponatinib—BCR—cerebellum—Parkinson's disease	0.000614	0.0053	CbGeAlD
Ponatinib—FLT3—cerebellum—Parkinson's disease	0.00061	0.00526	CbGeAlD
Ponatinib—KDR—cardiovascular system—Parkinson's disease	0.000602	0.0052	CbGeAlD
Ponatinib—FGFR2—spinal cord—Parkinson's disease	0.000586	0.00505	CbGeAlD
Ponatinib—LYN—brain—Parkinson's disease	0.000579	0.005	CbGeAlD
Ponatinib—FGFR3—brain—Parkinson's disease	0.000576	0.00497	CbGeAlD
Ponatinib—TEK—midbrain—Parkinson's disease	0.000576	0.00497	CbGeAlD
Ponatinib—ABL1—brainstem—Parkinson's disease	0.000569	0.00491	CbGeAlD
Ponatinib—TEK—spinal cord—Parkinson's disease	0.000562	0.00484	CbGeAlD
Ponatinib—RET—head—Parkinson's disease	0.000548	0.00473	CbGeAlD
Ponatinib—FGFR1—cerebellum—Parkinson's disease	0.000546	0.00471	CbGeAlD
Ponatinib—KIT—cardiovascular system—Parkinson's disease	0.000534	0.00461	CbGeAlD
Ponatinib—FGFR2—head—Parkinson's disease	0.000521	0.00449	CbGeAlD
Ponatinib—RET—nervous system—Parkinson's disease	0.000519	0.00448	CbGeAlD
Ponatinib—KDR—medulla oblongata—Parkinson's disease	0.000515	0.00444	CbGeAlD
Ponatinib—PDGFRA—spinal cord—Parkinson's disease	0.000509	0.00439	CbGeAlD
Ponatinib—RET—central nervous system—Parkinson's disease	0.0005	0.00431	CbGeAlD
Ponatinib—TEK—head—Parkinson's disease	0.000499	0.00431	CbGeAlD
Ponatinib—SRC—spinal cord—Parkinson's disease	0.000499	0.0043	CbGeAlD
Ponatinib—BCR—brain—Parkinson's disease	0.000499	0.0043	CbGeAlD
Ponatinib—FGFR2—nervous system—Parkinson's disease	0.000494	0.00426	CbGeAlD
Ponatinib—RET—cerebellum—Parkinson's disease	0.000489	0.00422	CbGeAlD
Ponatinib—FGFR2—central nervous system—Parkinson's disease	0.000475	0.0041	CbGeAlD
Ponatinib—TEK—nervous system—Parkinson's disease	0.000473	0.00408	CbGeAlD
Ponatinib—KDR—midbrain—Parkinson's disease	0.00047	0.00406	CbGeAlD
Ponatinib—ABL1—cardiovascular system—Parkinson's disease	0.000465	0.00401	CbGeAlD
Ponatinib—FGFR2—cerebellum—Parkinson's disease	0.000464	0.00401	CbGeAlD
Ponatinib—KDR—spinal cord—Parkinson's disease	0.000459	0.00396	CbGeAlD
Ponatinib—KIT—medulla oblongata—Parkinson's disease	0.000456	0.00393	CbGeAlD
Ponatinib—TEK—central nervous system—Parkinson's disease	0.000456	0.00393	CbGeAlD
Ponatinib—PDGFRA—head—Parkinson's disease	0.000452	0.0039	CbGeAlD
Ponatinib—TEK—cerebellum—Parkinson's disease	0.000445	0.00384	CbGeAlD
Ponatinib—FGFR1—brain—Parkinson's disease	0.000444	0.00383	CbGeAlD
Ponatinib—SRC—head—Parkinson's disease	0.000443	0.00383	CbGeAlD
Ponatinib—CYP2D6—hindbrain—Parkinson's disease	0.000429	0.00371	CbGeAlD
Ponatinib—PDGFRA—nervous system—Parkinson's disease	0.000429	0.0037	CbGeAlD
Ponatinib—SRC—nervous system—Parkinson's disease	0.00042	0.00363	CbGeAlD
Ponatinib—KIT—midbrain—Parkinson's disease	0.000417	0.0036	CbGeAlD
Ponatinib—PDGFRA—central nervous system—Parkinson's disease	0.000413	0.00356	CbGeAlD
Ponatinib—KDR—head—Parkinson's disease	0.000408	0.00352	CbGeAlD
Ponatinib—KIT—spinal cord—Parkinson's disease	0.000407	0.00351	CbGeAlD
Ponatinib—SRC—central nervous system—Parkinson's disease	0.000405	0.00349	CbGeAlD
Ponatinib—PDGFRA—cerebellum—Parkinson's disease	0.000403	0.00348	CbGeAlD
Ponatinib—ABL1—medulla oblongata—Parkinson's disease	0.000397	0.00343	CbGeAlD
Ponatinib—RET—brain—Parkinson's disease	0.000397	0.00343	CbGeAlD
Ponatinib—SRC—cerebellum—Parkinson's disease	0.000396	0.00341	CbGeAlD
Ponatinib—KDR—nervous system—Parkinson's disease	0.000387	0.00334	CbGeAlD
Ponatinib—FGFR2—brain—Parkinson's disease	0.000377	0.00325	CbGeAlD
Ponatinib—KDR—central nervous system—Parkinson's disease	0.000372	0.00321	CbGeAlD
Ponatinib—KDR—cerebellum—Parkinson's disease	0.000364	0.00314	CbGeAlD
Ponatinib—ABL1—midbrain—Parkinson's disease	0.000363	0.00313	CbGeAlD
Ponatinib—TEK—brain—Parkinson's disease	0.000362	0.00312	CbGeAlD
Ponatinib—KIT—head—Parkinson's disease	0.000361	0.00312	CbGeAlD
Ponatinib—ABL1—spinal cord—Parkinson's disease	0.000354	0.00305	CbGeAlD
Ponatinib—KIT—nervous system—Parkinson's disease	0.000343	0.00296	CbGeAlD
Ponatinib—KIT—central nervous system—Parkinson's disease	0.00033	0.00285	CbGeAlD
Ponatinib—PDGFRA—brain—Parkinson's disease	0.000328	0.00283	CbGeAlD
Ponatinib—Nilotinib—CYP2D6—Parkinson's disease	0.000326	0.0417	CrCbGaD
Ponatinib—KIT—cerebellum—Parkinson's disease	0.000323	0.00278	CbGeAlD
Ponatinib—SRC—brain—Parkinson's disease	0.000321	0.00277	CbGeAlD
Ponatinib—ABL1—head—Parkinson's disease	0.000315	0.00271	CbGeAlD
Ponatinib—ABL1—nervous system—Parkinson's disease	0.000298	0.00257	CbGeAlD
Ponatinib—KDR—brain—Parkinson's disease	0.000296	0.00255	CbGeAlD
Ponatinib—ABL1—central nervous system—Parkinson's disease	0.000287	0.00248	CbGeAlD
Ponatinib—ABL1—cerebellum—Parkinson's disease	0.000281	0.00242	CbGeAlD
Ponatinib—Imatinib—CYP2D6—Parkinson's disease	0.000272	0.0348	CrCbGaD
Ponatinib—KIT—brain—Parkinson's disease	0.000262	0.00226	CbGeAlD
Ponatinib—ABCG2—medulla oblongata—Parkinson's disease	0.00025	0.00216	CbGeAlD
Ponatinib—CYP2D6—brainstem—Parkinson's disease	0.000246	0.00212	CbGeAlD
Ponatinib—CYP2D6—forebrain—Parkinson's disease	0.000238	0.00205	CbGeAlD
Ponatinib—Nilotinib—ABCB1—Parkinson's disease	0.000233	0.0298	CrCbGaD
Ponatinib—ABCG2—midbrain—Parkinson's disease	0.000229	0.00197	CbGeAlD
Ponatinib—ABL1—brain—Parkinson's disease	0.000228	0.00197	CbGeAlD
Ponatinib—ABCG2—spinal cord—Parkinson's disease	0.000223	0.00193	CbGeAlD
Ponatinib—Imatinib—ABCB1—Parkinson's disease	0.000194	0.0248	CrCbGaD
Ponatinib—ABCB1—embryo—Parkinson's disease	0.000193	0.00167	CbGeAlD
Ponatinib—ABCG2—cerebellum—Parkinson's disease	0.000177	0.00153	CbGeAlD
Ponatinib—ABCB1—forebrain—Parkinson's disease	0.000171	0.00147	CbGeAlD
Ponatinib—CYP2C8—brain—Parkinson's disease	0.000148	0.00128	CbGeAlD
Ponatinib—ABCB1—cardiovascular system—Parkinson's disease	0.000145	0.00125	CbGeAlD
Ponatinib—ABCG2—brain—Parkinson's disease	0.000144	0.00124	CbGeAlD
Ponatinib—CYP2D6—head—Parkinson's disease	0.000136	0.00117	CbGeAlD
Ponatinib—CYP3A4—nervous system—Parkinson's disease	0.000131	0.00113	CbGeAlD
Ponatinib—CYP2D6—nervous system—Parkinson's disease	0.000129	0.00111	CbGeAlD
Ponatinib—CYP3A4—central nervous system—Parkinson's disease	0.000126	0.00109	CbGeAlD
Ponatinib—CYP2D6—central nervous system—Parkinson's disease	0.000124	0.00107	CbGeAlD
Ponatinib—ABCB1—medulla oblongata—Parkinson's disease	0.000123	0.00107	CbGeAlD
Ponatinib—CYP2D6—cerebellum—Parkinson's disease	0.000121	0.00105	CbGeAlD
Ponatinib—ABCB1—midbrain—Parkinson's disease	0.000113	0.000974	CbGeAlD
Ponatinib—ABCB1—spinal cord—Parkinson's disease	0.00011	0.00095	CbGeAlD
Ponatinib—CYP2D6—brain—Parkinson's disease	9.86e-05	0.00085	CbGeAlD
Ponatinib—ABCB1—head—Parkinson's disease	9.79e-05	0.000844	CbGeAlD
Ponatinib—ABCB1—nervous system—Parkinson's disease	9.28e-05	0.0008	CbGeAlD
Ponatinib—ABCB1—central nervous system—Parkinson's disease	8.93e-05	0.000771	CbGeAlD
Ponatinib—ABCB1—cerebellum—Parkinson's disease	8.73e-05	0.000753	CbGeAlD
Ponatinib—ABCB1—brain—Parkinson's disease	7.09e-05	0.000612	CbGeAlD
Ponatinib—FGFR1—Signaling Pathways—EDN1—Parkinson's disease	7.7e-06	3.89e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EDN1—Parkinson's disease	7.68e-06	3.88e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—DRD3—Parkinson's disease	7.66e-06	3.87e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—TNF—Parkinson's disease	7.66e-06	3.87e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MAOB—Parkinson's disease	7.66e-06	3.87e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—INS—Parkinson's disease	7.64e-06	3.86e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—TNF—Parkinson's disease	7.62e-06	3.85e-05	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—IL6—Parkinson's disease	7.62e-06	3.85e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—INS—Parkinson's disease	7.62e-06	3.85e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NGF—Parkinson's disease	7.59e-06	3.84e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HGF—Parkinson's disease	7.51e-06	3.8e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTA4—Parkinson's disease	7.48e-06	3.78e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—DDC—Parkinson's disease	7.47e-06	3.77e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GCH1—Parkinson's disease	7.46e-06	3.77e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NGF—Parkinson's disease	7.45e-06	3.77e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGB—Parkinson's disease	7.29e-06	3.69e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	7.29e-06	3.68e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—INS—Parkinson's disease	7.27e-06	3.67e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HTR1A—Parkinson's disease	7.25e-06	3.67e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HTR2A—Parkinson's disease	7.22e-06	3.65e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ADRBK1—Parkinson's disease	7.16e-06	3.62e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TAC1—Parkinson's disease	7.14e-06	3.61e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HTR2A—Parkinson's disease	7.09e-06	3.59e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IGF2—Parkinson's disease	7.09e-06	3.58e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NGF—Parkinson's disease	7.07e-06	3.57e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NGF—Parkinson's disease	7.05e-06	3.57e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTA4—Parkinson's disease	7.05e-06	3.56e-05	CbGpPWpGaD
Ponatinib—FGFR4—Disease—IL6—Parkinson's disease	7.04e-06	3.56e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	7.03e-06	3.55e-05	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—IL6—Parkinson's disease	7.02e-06	3.55e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—MAPK8—Parkinson's disease	7.01e-06	3.54e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—DRD1—Parkinson's disease	7.01e-06	3.54e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—IL6—Parkinson's disease	6.99e-06	3.54e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—COMT—Parkinson's disease	6.95e-06	3.51e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—IL6—Parkinson's disease	6.94e-06	3.51e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HTR7—Parkinson's disease	6.93e-06	3.5e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—DRD2—Parkinson's disease	6.93e-06	3.5e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MTHFR—Parkinson's disease	6.92e-06	3.5e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GSTP1—Parkinson's disease	6.92e-06	3.5e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—MAOA—Parkinson's disease	6.9e-06	3.49e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IGF1R—Parkinson's disease	6.85e-06	3.46e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—HMOX1—Parkinson's disease	6.82e-06	3.45e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—DRD3—Parkinson's disease	6.79e-06	3.43e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EDN1—Parkinson's disease	6.77e-06	3.42e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—INS—Parkinson's disease	6.76e-06	3.42e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PLA2G6—Parkinson's disease	6.74e-06	3.41e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HTR2A—Parkinson's disease	6.73e-06	3.4e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HTR2A—Parkinson's disease	6.71e-06	3.39e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—APOE—Parkinson's disease	6.71e-06	3.39e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MAOB—Parkinson's disease	6.67e-06	3.37e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—IL6—Parkinson's disease	6.66e-06	3.36e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GBA—Parkinson's disease	6.65e-06	3.36e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—FBP1—Parkinson's disease	6.65e-06	3.36e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—DBH—Parkinson's disease	6.65e-06	3.36e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL1B—Parkinson's disease	6.62e-06	3.35e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—APOE—Parkinson's disease	6.59e-06	3.33e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP2D6—Parkinson's disease	6.57e-06	3.32e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ABCB1—Parkinson's disease	6.55e-06	3.31e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—IL6—Parkinson's disease	6.54e-06	3.3e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL1B—Parkinson's disease	6.5e-06	3.29e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CTGF—Parkinson's disease	6.45e-06	3.26e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—APOE—Parkinson's disease	6.44e-06	3.26e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GSTM1—Parkinson's disease	6.36e-06	3.21e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	6.35e-06	3.21e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ADRBK1—Parkinson's disease	6.34e-06	3.2e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MAOB—Parkinson's disease	6.29e-06	3.18e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—IL6—Parkinson's disease	6.28e-06	3.18e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—APOE—Parkinson's disease	6.26e-06	3.16e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—APOE—Parkinson's disease	6.24e-06	3.16e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NGF—Parkinson's disease	6.22e-06	3.15e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CASP3—Parkinson's disease	6.21e-06	3.14e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—IL6—Parkinson's disease	6.2e-06	3.14e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—MAPK8—Parkinson's disease	6.2e-06	3.14e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—IL6—Parkinson's disease	6.19e-06	3.13e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—IL6—Parkinson's disease	6.18e-06	3.12e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL1B—Parkinson's disease	6.17e-06	3.12e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL1B—Parkinson's disease	6.16e-06	3.11e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—IL6—Parkinson's disease	6.15e-06	3.11e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—DRD2—Parkinson's disease	6.14e-06	3.1e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HTR7—Parkinson's disease	6.14e-06	3.1e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MTHFR—Parkinson's disease	6.13e-06	3.1e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GPX1—Parkinson's disease	6.09e-06	3.08e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—MAPK8—Parkinson's disease	6.07e-06	3.07e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP2E1—Parkinson's disease	6.01e-06	3.04e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—MAPK8—Parkinson's disease	5.96e-06	3.01e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NQO1—Parkinson's disease	5.94e-06	3e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HTR2A—Parkinson's disease	5.92e-06	2.99e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—TH—Parkinson's disease	5.86e-06	2.96e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF2—Parkinson's disease	5.81e-06	2.94e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—INS—Parkinson's disease	5.74e-06	2.9e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MAPK8—Parkinson's disease	5.71e-06	2.89e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—APOE—Parkinson's disease	5.71e-06	2.88e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP2D6—Parkinson's disease	5.69e-06	2.88e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—MAPK8—Parkinson's disease	5.66e-06	2.86e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—MAPK8—Parkinson's disease	5.64e-06	2.85e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL6—Parkinson's disease	5.64e-06	2.85e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—INS—Parkinson's disease	5.63e-06	2.85e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYCS—Parkinson's disease	5.62e-06	2.84e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—MTHFR—Parkinson's disease	5.62e-06	2.84e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF1R—Parkinson's disease	5.62e-06	2.84e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CTGF—Parkinson's disease	5.58e-06	2.82e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TNF—Parkinson's disease	5.56e-06	2.81e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EDN1—Parkinson's disease	5.55e-06	2.81e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—APOE—Parkinson's disease	5.51e-06	2.78e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—INS—Parkinson's disease	5.51e-06	2.78e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—IL6—Parkinson's disease	5.46e-06	2.76e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—IL6—Parkinson's disease	5.43e-06	2.75e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL1B—Parkinson's disease	5.43e-06	2.74e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CASP3—Parkinson's disease	5.41e-06	2.73e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL1B—Parkinson's disease	5.4e-06	2.73e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—INS—Parkinson's disease	5.35e-06	2.7e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—INS—Parkinson's disease	5.33e-06	2.7e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—APOE—Parkinson's disease	5.23e-06	2.64e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—IL6—Parkinson's disease	5.2e-06	2.63e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP2E1—Parkinson's disease	5.2e-06	2.63e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NQO1—Parkinson's disease	5.15e-06	2.6e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF2—Parkinson's disease	5.14e-06	2.6e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NGF—Parkinson's disease	5.1e-06	2.58e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TH—Parkinson's disease	5.07e-06	2.56e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—COMT—Parkinson's disease	4.98e-06	2.52e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—MAPK8—Parkinson's disease	4.98e-06	2.52e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MAPK8—Parkinson's disease	4.97e-06	2.51e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1R—Parkinson's disease	4.97e-06	2.51e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP2D6—Parkinson's disease	4.96e-06	2.51e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—MAPK8—Parkinson's disease	4.96e-06	2.51e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GSTP1—Parkinson's disease	4.95e-06	2.5e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MAOA—Parkinson's disease	4.94e-06	2.5e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL6—Parkinson's disease	4.93e-06	2.49e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EDN1—Parkinson's disease	4.91e-06	2.48e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—HMOX1—Parkinson's disease	4.89e-06	2.47e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—DDC—Parkinson's disease	4.88e-06	2.47e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—INS—Parkinson's disease	4.87e-06	2.46e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYCS—Parkinson's disease	4.87e-06	2.46e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CTGF—Parkinson's disease	4.87e-06	2.46e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HTR2A—Parkinson's disease	4.85e-06	2.45e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—INS—Parkinson's disease	4.7e-06	2.38e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ABCB1—Parkinson's disease	4.69e-06	2.37e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTA4—Parkinson's disease	4.61e-06	2.33e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CTGF—Parkinson's disease	4.59e-06	2.32e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GSTM1—Parkinson's disease	4.55e-06	2.3e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP2E1—Parkinson's disease	4.53e-06	2.29e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NGF—Parkinson's disease	4.51e-06	2.28e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—APOE—Parkinson's disease	4.51e-06	2.28e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—IL6—Parkinson's disease	4.48e-06	2.27e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NQO1—Parkinson's disease	4.48e-06	2.27e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—IL6—Parkinson's disease	4.47e-06	2.26e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—INS—Parkinson's disease	4.47e-06	2.26e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1B—Parkinson's disease	4.45e-06	2.25e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TH—Parkinson's disease	4.42e-06	2.23e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GPX1—Parkinson's disease	4.36e-06	2.2e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—COMT—Parkinson's disease	4.31e-06	2.18e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HTR2A—Parkinson's disease	4.3e-06	2.17e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTP1—Parkinson's disease	4.29e-06	2.17e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MAOA—Parkinson's disease	4.28e-06	2.16e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	4.27e-06	2.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CASP3—Parkinson's disease	4.27e-06	2.16e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYCS—Parkinson's disease	4.24e-06	2.14e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—HMOX1—Parkinson's disease	4.23e-06	2.14e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NQO1—Parkinson's disease	4.22e-06	2.14e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CASP3—Parkinson's disease	4.19e-06	2.12e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TH—Parkinson's disease	4.16e-06	2.1e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	4.15e-06	2.1e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MAOB—Parkinson's disease	4.11e-06	2.08e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK8—Parkinson's disease	4.08e-06	2.06e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ABCB1—Parkinson's disease	4.06e-06	2.05e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MTHFR—Parkinson's disease	4.02e-06	2.03e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYCS—Parkinson's disease	4e-06	2.02e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APOE—Parkinson's disease	4e-06	2.02e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CASP3—Parkinson's disease	3.98e-06	2.01e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CASP3—Parkinson's disease	3.97e-06	2.01e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—IL6—Parkinson's disease	3.96e-06	2e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTM1—Parkinson's disease	3.94e-06	1.99e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1B—Parkinson's disease	3.94e-06	1.99e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK8—Parkinson's disease	3.93e-06	1.98e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—Parkinson's disease	3.88e-06	1.96e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—INS—Parkinson's disease	3.86e-06	1.95e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK8—Parkinson's disease	3.86e-06	1.95e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—Parkinson's disease	3.81e-06	1.92e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GPX1—Parkinson's disease	3.78e-06	1.91e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—COMT—Parkinson's disease	3.76e-06	1.9e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOE—Parkinson's disease	3.75e-06	1.89e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTP1—Parkinson's disease	3.74e-06	1.89e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MAOA—Parkinson's disease	3.73e-06	1.89e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HMOX1—Parkinson's disease	3.69e-06	1.86e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK8—Parkinson's disease	3.66e-06	1.85e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK8—Parkinson's disease	3.65e-06	1.84e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—Parkinson's disease	3.64e-06	1.84e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—Parkinson's disease	3.61e-06	1.83e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK8—Parkinson's disease	3.61e-06	1.83e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—Parkinson's disease	3.6e-06	1.82e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—Parkinson's disease	3.58e-06	1.81e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—COMT—Parkinson's disease	3.54e-06	1.79e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTP1—Parkinson's disease	3.52e-06	1.78e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—Parkinson's disease	3.52e-06	1.78e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MAOA—Parkinson's disease	3.52e-06	1.78e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—Parkinson's disease	3.5e-06	1.77e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—Parkinson's disease	3.49e-06	1.76e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HMOX1—Parkinson's disease	3.47e-06	1.76e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTM1—Parkinson's disease	3.44e-06	1.74e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—INS—Parkinson's disease	3.41e-06	1.73e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—Parkinson's disease	3.34e-06	1.69e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCB1—Parkinson's disease	3.34e-06	1.69e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—Parkinson's disease	3.33e-06	1.68e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GPX1—Parkinson's disease	3.29e-06	1.66e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOE—Parkinson's disease	3.24e-06	1.64e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—Parkinson's disease	3.24e-06	1.64e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK8—Parkinson's disease	3.22e-06	1.63e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—INS—Parkinson's disease	3.2e-06	1.62e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—Parkinson's disease	3.18e-06	1.61e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—Parkinson's disease	3.17e-06	1.6e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—Parkinson's disease	3.16e-06	1.6e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GPX1—Parkinson's disease	3.1e-06	1.57e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	3.05e-06	1.54e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—Parkinson's disease	3.04e-06	1.54e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CTGF—Parkinson's disease	3e-06	1.52e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—Parkinson's disease	2.87e-06	1.45e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—Parkinson's disease	2.86e-06	1.45e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOE—Parkinson's disease	2.83e-06	1.43e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	2.79e-06	1.41e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—INS—Parkinson's disease	2.77e-06	1.4e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NQO1—Parkinson's disease	2.76e-06	1.4e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TH—Parkinson's disease	2.72e-06	1.38e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOE—Parkinson's disease	2.66e-06	1.35e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK8—Parkinson's disease	2.64e-06	1.33e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYCS—Parkinson's disease	2.61e-06	1.32e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—Parkinson's disease	2.61e-06	1.32e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—Parkinson's disease	2.54e-06	1.28e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—Parkinson's disease	2.51e-06	1.27e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—Parkinson's disease	2.46e-06	1.24e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—INS—Parkinson's disease	2.42e-06	1.22e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—Parkinson's disease	2.41e-06	1.22e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—Parkinson's disease	2.34e-06	1.18e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK8—Parkinson's disease	2.34e-06	1.18e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—Parkinson's disease	2.33e-06	1.18e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—COMT—Parkinson's disease	2.31e-06	1.17e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—Parkinson's disease	2.31e-06	1.17e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—Parkinson's disease	2.3e-06	1.16e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MAOA—Parkinson's disease	2.3e-06	1.16e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—INS—Parkinson's disease	2.28e-06	1.15e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMOX1—Parkinson's disease	2.27e-06	1.15e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCB1—Parkinson's disease	2.18e-06	1.1e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—Parkinson's disease	2.13e-06	1.08e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—Parkinson's disease	2.12e-06	1.07e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—Parkinson's disease	2.06e-06	1.04e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPX1—Parkinson's disease	2.03e-06	1.02e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—Parkinson's disease	1.87e-06	9.46e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOE—Parkinson's disease	1.74e-06	8.8e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—Parkinson's disease	1.68e-06	8.52e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—Parkinson's disease	1.49e-06	7.54e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—INS—Parkinson's disease	1.49e-06	7.52e-06	CbGpPWpGaD
